Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

BACKGROUND: Fulvestrant 500 mg (F500) is the most active endocrine single agent in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Few data are available regarding the effectiveness of the drug in a real-world setting. PATIENTS AND METHODS: This prospective, multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Palumbo, Raffaella, Sottotetti, Federico, Quaquarini, Erica, Gambaro, Anna, Ferzi, Antonella, Tagliaferri, Barbara, Teragni, Cristina, Licata, Luca, Serra, Francesco, Lapidari, Pietro, Bernardo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552357/
https://www.ncbi.nlm.nih.gov/pubmed/31210797
http://dx.doi.org/10.1177/1758835919833864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552357/
https://www.ncbi.nlm.nih.gov/pubmed/31210797
http://dx.doi.org/10.1177/1758835919833864

Ejemplares similares